In a previous study, we evaluated the potential benefits and costs of population-wide screening for CKD combined with the provision of angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) plus SGLT2 inhibitors. Here, ACE is linked to chronic kidney disease.